ArticleJournal of applied clinical medical physics2022
Validation of Monte Carlo dose calculation algorithm for CyberKnife multileaf collimator.
Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 6 citations in OpenAlex.
- Increasing demands on commissioning and quality assurance for cone-based multiple brain metastases robotic radiosurgery: evaluation in a custom phantom.Physical and engineering sciences in medicine · 2026Article
- Dosimetric comparison of FF and FFF modes under non-ideal bolus-fitting conditions for post-mastectomy chest wall irradiations.Journal of applied clinical medical physics · 2026Article
- Dosimetric comparison of M6 CyberKnife plans optimized with Precision and RayStation 12A treatment planning systems.Journal of applied clinical medical physics · 2025Article
- Clinical application of a GPU-accelerated monte carlo dose verification for cyberknife M6 with Iris collimator.Radiation oncology (London, England) · 2024Article
- A novel Monte Carlo (MC) dose model for small MLC fields of the cyberknifeJournal of applied clinical medical physics · 2023Article
- Commissioning and validation of RayStation treatment planning system for CyberKnife M6.Journal of applied clinical medical physics · 2022Article
- Validation of Monte Carlo dose calculation algorithm for CyberKnife multileaf collimator.Journal of applied clinical medical physics · 2022Article
- Assessing Heterogeneity Effects on Points A, B, and Organs at Risk Doses in High-dose-Rate Brachytherapy for Cervical Cancer - A Comparison ofJournal of medical physicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo commission and evaluate the Monte Carlo (MC) dose calculation algorithm for the CyberKnife equipped with a multileaf collimator (MLC).
methodsWe created a MC model for the MLC using an integrated module of the CyberKnife treatment planning software (TPS). Two parameters could be optimized: the maximum energy and the source full width at half-maximum (FWHM). The optimization was performed by minimizing the differences between the measured and the MC calculated tissue phantom ratios and profiles. MLC plans were calculated in the TPS with the MC algorithm and irradiated on different phantoms. The dose was measured using an A1SL ionization chamber and EBT3 Gafchromic films, and then compared to the TPS dose to obtain dose differences (ΔD). Finally, patient-specific quality assurances (QA) were performed with global gamma index criteria of 3%/1 mm.
resultsThe maximum energy and source FWHM showing the best agreement with measurements were 6.4 MeV and 1.8 mm. The output factors calculated with these parameters gave an agreement within ±1% with measurements. The ΔD showed that MC model systematically underestimated the dose with an average of -1.5% over all configurations tested. For depths deeper than 12 cm, the ΔD increased, up to -3.0% (maximum at 15.5 cm depth).
conclusionsThe MC model for MLC of CyberKnife is clinically acceptable but underestimates the delivered dose by an average of -1.5%. Therefore, we recommend using the MC algorithm with the MLC only in heterogeneous regions and for shallow-seated tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.